Swiss National Bank
NWBO

Swiss National Bank’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Swiss National Bank’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-85,600
Closed -$121K – 2662
2016
Q1 		$121K Buy
85,600
+18,400
+27% +$36.3K ﹤0.01% 2594
2015
Q4 		$215K Hold
67,200
– – ﹤0.01% 2567
2015
Q3 		$420K Buy
67,200
+12,200
+22% +$114K ﹤0.01% 2271
2015
Q2 		$546K Buy
+55,000
New +$482K ﹤0.01% 2188

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Swiss National Bank's NWBO Position: Q2 2016 in Review

Swiss National Bank sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 85,600 shares — an estimated $121K sold.

Swiss National Bank first reported a position in NWBO in Q2 2015 and held it in 4 quarters. The position peaked at $546K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

  • Swiss National Bank reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
  • Swiss National Bank sold 85,600 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $121K.
  • Swiss National Bank first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2015 and held it in 4 quarters.
  • Swiss National Bank's Northwest Biotherapeutics, Inc. Common stock position peaked at $546K in Q2 2015.
  • 64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Swiss National Bank's 13F filing for Q2 2016, filed 3 Aug 2016.